PHASE II STUDY OF 9-AMINOCAMPTOTHECIN IN CHRONIC LYMPHOCYTIC LEUKEMIA

9-氨基喜树碱治疗慢性淋巴细胞白血病的 II 期研究

• 批准号: 6245483
• 负责人: MICHAEL R GREVER
• 金额: $ 2.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-05 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245483
• 关键词: brca gene; camptothecin; chronic lymphocytic leukemia; circulating neoplastic cell; clinical research; human subject; human therapy evaluation; molecular oncology; multidrug resistance; neoplasm /cancer chemotherapy; tumor suppressor genes

Seven patients have been entered on this phase II trial. Two additional patients are scheduled to begin treatment the week of (1/13/97). A tenth patient is being evaluated at Walter Reed Army Hospital this week for potential enrollment on the study. We have enlisted the participation of this second institution to increase the rate of accrual. The overall minimal accrual goal will be 14 patients. Leukemic cells from patients have been examined in the laboratory. We are examining p53, mdr-1 and bcl-2 expression. Cells are also being examined for induction of apoptosis. We have had difficulty in setting up the assay to quantify retention of the cleavable complex. The published method has not been reproducible. Samples have been retained to determine if this important pharmacodynamic parameter can be measured by another method.

七名患者已进入这项 II 期试验。另外两个 患者计划于 (1/13/97) 一周开始治疗。 十分之一 患者本周正在沃尔特·里德陆军医院接受评估 该研究的潜在入学率。我们已经征集了以下人士的参与 这第二个机构提高了应计比率。整体 最低应计目标是 14 名患者。 来自患者的白血病细胞已在实验室进行了检查。我们是 检查 p53、mdr-1 和 bcl-2 表达。细胞也正在接受检查 用于诱导细胞凋亡。 我们在建立 定量可裂解复合物保留的测定。已发表的方法 尚未被重现。已保留样品以确定这是否 重要的药效学参数可以通过另一种方法测量。